Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9527210.26442/20751753.2020.8.200194Research ArticleThe effectiveness of adding butyric acid to antispasmodic therapy regimens for irritable bowel syndrome: a meta-analysis of controlled studiesAndreevDmitrii N.dna-mit8@mail.ruKucheryavyyYury A.-CheremushkinSergei V.-MaevIgor V.-Yevdokimov Moscow State University of Medicine and Dentistry15082020228273128122021Copyright © 2020, Consilium Medicum2020Aim. Systematization of data on the effectiveness of adding butyric acid in the antispasmodic treatment regimens for irritable bowel syndrome (IBS) as a part of meta-analysis. Outcomes and methods. Searching for studies was performed using the MEDLINE / PubMed, EMBASE, Cochrane, Russian Science Citation Index electronic databases for a period till June 2020. All controlled studies comparing the effectiveness of abdominal pain relief in patients with IBS with a combination of butyric acid and standard antispasmodic therapy were included in the final analysis. Results. We selected 8 controlled studies (all from Russia) which included totally 708 patients (412 in the groups of butyric acid and antispasmodic drug combined therapy; 296 in the groups of antispasmodic drug monotherapy). The overall effectiveness of abdominal pain relief in the combined therapy groups was 76.31% (95% confidence interval -CI 71.947-80.298), while in the monotherapy groups - 33,58% (95% CI 28.294-39.199). A meta-analysis showed that adding butyric acid to antispasmodic therapy significantly increases the effectiveness of achieving a complete regression of abdominal pain in patients with IBS (odds ratio 5.995, 95% CI 4.282-8.395, p<0,001) compared with monotherapy. There was no significant heterogeneity between the data of studies (p=0.3335; I2=12.38%). Conclusions. This meta-analysis demonstrated that adding butyric acid to antispasmodic therapy regimens for IBS significantly increases the rate of abdominal pain relief.irritable bowel syndromebutyric acidbutyrateantispasmodic drugpainvisceral hypersensitivityсиндром раздраженного кишечникамасляная кислотабутиратспазмолитикбольвисцеральная гиперчувствительность[Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Андреев Д.Н. Синдром раздраженного кишечника с позиций современной фундаментальной и клинической медицины. М., 2019.][Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020. DOI: 10.1038/s41575-020-0286-8][Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-ana-lysis. Clin Gastroenterol Hepatol 2012; 10 (7): 712-21.e4. DOI: 10.1016/j.cgh.2012.02.029][Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis. PLoS One 2015; 10 (5): e0126982. DOI: 10.1371tjournal.pone.0126982][Zielinska A, Sataga M, Wtodarczyk M, Fichna J. Chronic abdominal pain in irritable bowel syndrome - current and future therapies. Expert Rev Clin Pharmacol 2018; 11 (7): 729-39.][Mearin F, Lacy BE, Chang L et al. Bowel Disorders. Gastroenterology 2016: S0016-5085(16)00222-5. DOI: 10.1053/j.gastro.2016.02.031][Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2017; 27 (5): 76-93. DOI: 10.22416/1382-4376-2017-27-5-76-93][Poynard T Regimbeau C, Benhamou Y Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15 (3): 355-61. DOI: 10.1046/j.1365-2036.2001.00937.x][Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313. DOI: 10.1136/bmj.a2313][Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. World J Gastroenterol 2018; 24 (21): 2211-35. DOI: 10.3748/wjg.v24.i21.2211][Zatpski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome. Prz Gastroenterol 2013; 8 (6): 350-3. DOI: 10.5114/pg.2013.39917][Manrique Vergara D, Gonzalez Sanchez ME. Short chain fatty acids (butyric acid) and intestinal diseases. Nutr Hosp 2017; 34 (Suppl. 4): 58-61. DOI: 10.20960/nh.1573][Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012; 15 (5): 474-9. DOI: 10.1097/MCO.0b013e32835665fa][Nozu T, Miyagishi S, Nozu R et al. Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome. Sci Rep 2019; 9 (1): 19603. DOI: 10.1038/s41598-019-56132-4][Vanhoutvin SA, Troost FJ, Kilkens TO et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21 (9): 952-e76. DOI: 10.1111/j.1365-2982.2009.01324.x][Banasiewicz T, Krokowicz t, Stojcev Z et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis 2013; 15 (2): 204-9. DOI: 10.1111/j.1463-1318.2012.03152.X][Ардатская М.Д., Топчий Т.Б., Лощинина Ю.Н., Калашникова М.А. Клиническая эффективность масляной кислоты и инулина в купировании болевого синдрома у пациентов с синдромом раздраженной кишки. Лечащий врач. 2015; 12: 79-85.][Немцов В.И. Синдром раздраженной кишки (СРК): новые представления об этиопатогенезе и лечении. Лечащий врач. 2015; 6: 60-5.][Корочанская Н.,Серикова С., Васькова Е. Комплексная медикаментозная терапия пациентов с разными типами синдрома раздраженной кишки. Врач. 2016; 6: 45-9.][Приходько Е.М., Цурцумия Д.Б., Селиверстов П.В. и др. Возможности современной терапии у пациентов с синдромом раздраженного кишечника. Лечащий врач. 2016; 8: 76-9.][Сарсенбаева А., Смолягина А., Уфимцев К., Иванова Е. Синдром раздраженного кишечника: некоторые аспекты патогенеза и комплексной терапии. Врач. 2016; 10: 52-6.][Козлова Н.М., Меринова Н.И. Эффективность применения комбинированного препарата масляной кислоты у пациентов с синдромом раздраженного кишечника. Лечащий врач. 2017; 4:51-5.][Левченко С.В., Комиссаренко И.А., Голохвастова А.А. и др. Эффективность масляной кислоты и инулина у больных синдромом раздраженного кишечника: результаты многоцентрового исследования. Лечащий врач. 2018; 2: 53-60.][Бутова Е.Н. Оптимизация современной терапии пациентов с синдромом раздраженного кишечника. Лечащий врач. 2019; 7: 53-9.][Oswipcimska J, Szymlak A, Roczniak W et al. New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv Med Sci 2017; 62 (1): 17-30. DOI: 10.1016/j.advms.2016.11.001][Tarnowski W, Borycka-Kiciak K, Kiciak A. Outcome of treatment with butyric acid In irritable bowel syndrome - preliminary report. Gastroenterol Prakt 2011; 1: 43-8.][Андреев Д.Н., Дичева Д.Т. Нарушение проницаемости слизистой оболочки кишечника как фактор этиопатогенеза функциональных заболеваний желудочно-кишечного тракта. Мед. совет. 2020; 5: 87-95. DOI: 10.21518/2079-701X-2020-5-87-95][Ng QX, Soh AYS, Loke W et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res 2018;11:345-9.][Bashashati M, Moossavi S, Cremon C et al. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil 2018; 30 (1). DOI: 10.1111/nmo.13192][Lee KN, Lee OY. The Role of Mast Cells in Irritable Bowel Syndrome. Gastroenterol Res Pract 2016; 2016:2031480.][Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132 (1): 26-37. DOI: 10.1053/j.ga-stro.2006.11.039][Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137 (4): 1425-34. DOI: 10.1053/j.gastro.2009.07.005][Zhang H, Du M, Yang Q, Zhu MJ. Butyrate suppresses murine mast cell proliferation and cytokine production through inhibiting histone deacetylase. J Nutr Biochem 2016; 27: 299-306. DOI: 10.1016/j.jnutbio.2015.09.020][Wang CC, Wu H, Lin FH et al. Sodium butyrate enhances intestinal integrity, inhibits mast cell activation, inflammatory mediator production and JNK signaling pathway in weaned pigs. Innate Immun 2018; 24 (1): 40-6. DOI: 10.1177/1753425917741970][Folkerts J, Redegeld F, Folkerts G et al. Butyrate inhibits human mast cell activation via epigenetic regulation of FceRI-mediated signaling. Allergy 2020. DOI: 10.1111/all.14254][Fu X, Liu Z, Zhu C et al. Nondigestible carbohydrates, butyrate, and butyrate-producing bacteria. Crit Rev Food Sci Nutr 2019; 59 (Suppl 1): S130-S152. DOI: 10.1080/10408398.2018.1542587][Miquel S, Martin R, Lashermes A et al. Anti-nociceptive effect of Faecalibacterium prausnitzii in noninflammatory IBS-like models. Sci Rep 2016; 6: 19399. DOI: 10.1038/srep19399][Zhao K, Yu L, Wang X et al. Clostridium butyricum regulates visceral hypersensitivity of irritable bowel syndrome by inhibiting colonic mucous low grade inflammation through its action on NLRP6. Acta Biochim Biophys Sin (Shanghai) 2018; 50 (2): 216-23. DOI: 10.1093/abbs/gmx138]